The ALS space takes another hit after experimental drug BIIB105 failed to show evidence of benefit in patients in the Phase I ...
Uniquity is planning Phase II trials in COPD and asthma with TSLP-targeting drug solrikitug that it licensed from MSD ...
IgGenix is planning to initiate a clinical trial later this year investigating its peanut allergy monoclonal antibody IGXN001 ...
GIP receptor agonist, which was gained in the Carmot acquisition, showed an 18.8% weight loss in a Phase Ib trial.
AstraZeneca has incorporated a new target for heart failure into its discovery portfolio, a result of its collaboration with ...
In this series, life sciences industry M&A veteran John Easton will discuss how digital deals differ from traditional life ...
The next frontier in the NSCLC space appears to be drugs that go beyond targeting the G12C domain and can treat other types ...
The US National Opioid Settlement is distributing more than $54 billion to communities grappling with the opioid crisis.
Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.
Bexicaserin is a small molecule commercialized by Longboard Pharmaceuticals, with a leading Phase II program in Lennox-Gastaut Syndrome. According to Globaldata, it is involved in 12 clinical trials, ...
Osivelotor is a small molecule commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease.
Brogidirsen is an antisense oligonucleotide commercialized by Nippon Shinyaku, with a leading Phase II program in Duchenne Muscular Dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results